Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter explains why getting a second opinion changed the course of her care.
|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related to this article
Noah Elliott, now a Paralympic snowboarder, counted small wins during inpatient chemotherapy and found inspiration in the youngest children on his hospital floor.
In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.
Advertisement
Advertisement
Trending on CURE
1
Stage 4 Breast Cancer: How a Second Opinion Saved Her Life
2
Psycho-Oncologist Answers 5 Common Questions About the Emotional Impact of Cancer
3
FDA Flags Possible Colitis Risk With CDK4/6 Breast Cancer Drugs
4
How a Cancer Survivor Learned to Stop Hiding His Surgical Scars
5